Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma

被引:0
|
作者
Matthew J. Ahearne
Kaljit Bhuller
Roger Hew
Hazem Ibrahim
Kikkeri Naresh
Simon D. Wagner
机构
[1] University of Leicester,Department of Cancer Studies and Molecular Medicine, Ernest and Helen Scott Haematology Research Institute and MRC Toxicology Unit
[2] Leicester Royal Infirmary,Department of Haematology
[3] Leicester Royal Infirmary,Department of Histopathology
[4] Imperial College Healthcare NHS Trust,Department of Histopathology
[5] University of Leicester,MRC Toxicology Unit
来源
Virchows Archiv | 2014年 / 465卷
关键词
Tfh; Treg; Diffuse large B-cell lymphoma;
D O I
暂无
中图分类号
学科分类号
摘要
The role of the microenvironment in high-grade lymphoma is not well defined. In this report, we employ immunohistochemistry to characterise programmed death-1 (PD-1/CD279) and FoxP3 expression in 70 cases of diffuse large B-cell lymphoma (DLBCL). PD-1 is a surface marker characteristic of follicular helper T-cells whilst FoxP3 is characteristic of Tregs. We demonstrate variable infiltration with CD4+ T-cells (<10 to >50 % of all lymph node cells) and PD-1hi cells (0.1 to 1.5 % of all cells). CD4+ T-cells can be distributed in clusters or more diffusely and PD-1hi cells, but not FoxP3+ cells, are found in rosettes around lymphoma cells. Cases with high CD4+ T-cell numbers tended to have higher numbers of both PD-1hi and FoxP3+ cells. Cases with total CD4+ T-cell, PD-1hi and FoxP3+ numbers above the median associate with better clinical outcome. Overall, we demonstrate that infiltration by CD4+ T-cells, including both FoxP3+ and PD-1hi subsets, correlates with prognosis in DLBCL. In distinction to previous reported series, patients (91 %) were treated with rituximab-containing regimens, suggesting that the effects of CD4+ T-cell infiltration are maintained in the rituximab era. This work suggests that determinants of total CD4+ T-cell infiltration, either molecular characteristics of the lymphoma or the patients’ immune system, and not individual T-cell subsets, correlate with clinical outcome.
引用
收藏
页码:351 / 358
页数:7
相关论文
共 50 条
  • [1] Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma
    Ahearne, Matthew J.
    Bhuller, Kaljit
    Hew, Roger
    Ibrahim, Hazem
    Naresh, Kikkeri
    Wagner, Simon D.
    VIRCHOWS ARCHIV, 2014, 465 (03) : 351 - 358
  • [2] The Clinical and Biological Effects of PD-1 Expression on Tumor Cells in Diffuse Large B-Cell Lymphoma
    Hanamura, Ichiro
    Suzuki, Susumu
    Ota, Akinobu
    Murakami, Satsuki
    Satou, Akira
    Takahara, Taishi
    Karnan, Sivasundaram
    Lam, Vu Quang
    Nakamura, Ayano
    Takasugi, Souichi
    Yoshikawa, Kazuhiro
    Banno, Shogo
    Ejiri, Masayuki
    Tsuzuki, Toyonori
    Hosokawa, Yoshitaka
    Ueda, Ryuzo
    Takami, Akiyoshi
    HEMATO, 2021, 2 (02): : 368 - 382
  • [3] Expression of Foxp3 and interleukin-7 receptor and clinicopathological characteristics of patients with diffuse large B-cell lymphoma
    Zhao, Yan
    Cui, Wen-Li
    Feng, Zhi-Yin
    Xue, Jing
    Gulinaer, Abulajiang
    Zhang, Wei
    ONCOLOGY LETTERS, 2020, 19 (04) : 2755 - 2764
  • [4] Preliminary study on decreasing the expression of FOXP3 with miR-155 to inhibit diffuse large B-cell lymphoma
    Zhang, Jincheng
    Wei, Bin
    Hu, Huixian
    Liu, Fanrong
    Tu, Yan
    Zhao, Minzhe
    Wu, Dongmei
    ONCOLOGY LETTERS, 2017, 14 (02) : 1711 - 1718
  • [5] PD-1 Expression Is Upregulated in Diffuse Large B-Cell Lymphoma Transformed from Marginal Zone Lymphoma and Significantly Higher in Comparison with de novo Diffuse Large B-Cell Lymphoma
    Zhang, Shanxiang
    LABORATORY INVESTIGATION, 2019, 99
  • [6] PD-1 Expression Is Upregulated in Diffuse Large B-Cell Lymphoma Transformed from Marginal Zone Lymphoma and Significantly Higher in Comparison with de novo Diffuse Large B-Cell Lymphoma
    Zhang, Shanxiang
    MODERN PATHOLOGY, 2019, 32
  • [7] CD37 tetraspanin as a novel biomarker for PD-1 blockade in diffuse large B-cell lymphoma
    Xu-Monette, Zijun Y.
    Young, Ken H.
    CANCER RESEARCH, 2017, 77
  • [8] The significance of FOXP1 in diffuse large B-cell lymphoma
    Gascoyne, Duncan M.
    Banham, Alison H.
    LEUKEMIA & LYMPHOMA, 2017, 58 (05) : 1037 - 1051
  • [9] Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma
    Saber, Manal Mohamed
    ANTIBODIES, 2022, 11 (01)
  • [10] CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma
    Kwiecinska, Anna
    Tsesmetzis, Nikolaos
    Ghaderi, Mehran
    Kis, Lorand
    Saft, Leonie
    Rassidakis, George Z.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (05) : 744 - 748